empty
 
 
it
Search
Supporto
Apertura rapida di un conto
Piattaforma di trading
Ricaricare / Prelevare
Search
Per principianti Per trader Per partner Fai una pausa Chi siamo
it
#ACB Tornare a tutti gli strumenti #AMGN

Convertitore di valute

Alnylam Pharmaceuticals Inc.
240.1 USD
09 Jan 2025 18:26
Variazione del prezzo (% chg)
$0
(0%)
Chiusura
Chiusura

Prezzo di chiusura, giorno precedente.
$240.1
Apertura
Apertura

Prezzo di apertura.
$234.37
Prezzo massimo
Prezzo massimo

Prezzo massimo nell'ultimo giorno di negoziazioni.
$240.1
Prezzo minimo
Prezzo minimo

Prezzo minimo nell'ultimo giorno di negoziazioni.
$240.1
Massimo 52 settimane.
Massimo 52 settimane.

Prezzo massimo nelle ultime 52 settimane.
$240.1
Mnimo 52 settimane.
Mnimo 52 settimane.

Prezzo minimo nelle ultime 52 settiimane.
$234
Scaricare l'archivio
Acquista
240.1
Vendi
240.1
Apri il grafico a schermo intero
Acquista
240.1
Vendi
240.1
Scaricare l'archivio
Apri il grafico a schermo intero

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

In questo momento non potete parlare al telefono?
Ponete la vostra domanda nella chat.